west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "XIANGBing" 2 results
  • Clinical Efficacy of Combined Immunosuppressant Therapy on Chronic Refractory Immune Thrombocytopenia Purpura and Its Effects on the Level of Platelete-associated antibody

    ObjectiveTo observe the clinical efficacy of combined immunosuppressant therapy for patients with chronic refractory immune thrombocytopenia purpura (ITP) and its effects on platelete-associated antibody (PAIG) level. MethodsBetween February 2009 and February 2013, 22 patients with refractory ITP were randomly divided into immunosuppressive drugs combination treatment group and single drug treatment group. The combination treatment group was treated with methylprednisolone and intravenous immunoglobulin (IVIG), and after the fast increasing of platelet count, combined chemotherapy consisting of two or three kinds of immunosuppressive agents was adopted. The single treatment group was also treated with methylprednisolone and IVIG, but took only one immunosuppressive agent after the fast increasing of platelet count. The treatment maintained for 3 to 6 months. The duration of follow-up was 6-36 months. We used flow cytometry to detect PAIG of the patients. ResultsThe total effective rate of combination treatment group was 81.8%, significantly higher than that of the single treatment group (36.4%) (P<0.05). PAIG decreased obviously in both the two groups, and the PAIG level of the combination treatment group was much lower than that of the single treatment group (P<0.05). ConclusionImmunosuppresant combination chemotherapy is a powerful approach for patients with refractory ITP, and it can decrease patient's PAIG level simultaneously.

    Release date: Export PDF Favorites Scan
  • Research on the Mechanism of Rosiglitazone in Improving Cognitive Impairment in Senile Diabetic Rats

    ObjectiveTo observe the effect of rosiglitazone on cognitive function, serum high sensitive C reactive protein (hs-CRP) and expression of nuclear factor-κB (NF-κB), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) in hippocampal tissues of senile diabetic rats. MethodsThirty aged Wistar rats (20-22 months) were randomly divided into normal control group (n=6), diabetic model group (n=12), and rosiglitazone treatment group (n=12). Streptozotocin-induced diabetic rat model was established. In the rosiglitazone treatment group, the rats were treated with rosiglitazone 4mg/kg/d for 8 weeks. The cognitive function of rats was evaluated with the Morris water maze test. Serum hs-CRP was detected by ELISA. The expression of NF-κB in hippocampal tissues was detected by western blot and IL-6 and TNF-α by Real-time PCR. ResultsThe Morris water maze test showed that escape latency was longer in the rosiglitazone treatment group and the diabetic model group than that in the control group (P<0. 05). Compared with the diabetic model group, the rosiglitazone treatment group showed a significant decrease in the average time of escape latencies (P<0.05), and an increased percentage of time spent in the central area and the more times navigating the original platform position (P<0.05). Serum hs-CRP and the expression of NF-κB, IL-6 and TNF-α in the rosiglitazone treatment group and the diabetic model group was significantly higher than those in the control group (P<0.01). Compared with the diabetic model group, serum hs-CRP and the expression of NF-κB, IL-6 and TNF-α in the rosiglitazone treatment group was decreased (P<0.05). ConclusionCognitive impairment in senile diabetic rats is associated with serum hs-CRP. The cognitive function can be improved with rosiglitazone treatment. The protective mechanisms may be related to the decrease of serum hs-CRP, inhibition of NF-κB signal and down-regulation of the expression of IL-6 and TNF-α in hippocampal tissues.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content